Best of IGCS 2022 Annual Global Meeting-Platinum-Sensitive Ovarian Cancer - Unmet Medical Need Beyond PARP Inhibitors - Industry Symposium by Mersana Therapeutics, Inc.

Platinum-Sensitive Ovarian Cancer - Unmet Medical Need Beyond PARP Inhibitors - Industry Symposium by Mersana Therapeutics, Inc.

Back to course

Video Transcription

Video Summary

Summary: <br />The videos discuss the topic of platinum-sensitive ovarian cancer and the challenges of developing effective treatment strategies beyond PARP inhibitors. They explore the mechanisms of platinum resistance and the importance of understanding the tumor microenvironment. The videos also highlight ongoing clinical trials investigating potential treatment options such as immune checkpoint inhibitors, antibody-drug conjugates, and resensitization to other PARP inhibitors. The audience response suggests that antibody-drug conjugates are considered a promising treatment strategy post-PARP inhibition. Overall, the videos emphasize the need for further research to overcome resistance and develop effective treatments for platinum-sensitive ovarian cancer.<br /><br />Credits: <br />The first video does not mention any specific credits for speakers or sources. <br />The second video does not provide specific credits for the speaker but involves the perspective of a patient advocate.

Keywords

platinum-sensitive ovarian cancer

PARP inhibitors

platinum resistance

tumor microenvironment

clinical trials

immune checkpoint inhibitors

antibody-drug conjugates

resensitization

treatment options

post-PARP inhibition

research